The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
408
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Chemotherapy (docetaxel and prednisone)
Survival
Time frame: 0
Time to disease progression. Time to pain progression.
Time frame: 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alaska Clinical Research Center
Anchorage, Alaska, United States
St. Edward Mercy Medical Center
Fort Smith, Arkansas, United States
Loma Linda University
Loma Linda, California, United States
Onocology Care Medical Associates
Los Angeles, California, United States
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States
San Bernardino Urology Associates
San Bernardino, California, United States
Kaiser Permanente Medical Group Dept. of Oncology Research
San Diego, California, United States
Sharp Healthcare
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
UCSF Mt. Zion Cancer Center
San Francisco, California, United States
...and 105 more locations